Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)J. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 227-234. DOI: 10.12290/xhyxzz.2022-0089
Citation: Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)J. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 227-234. DOI: 10.12290/xhyxzz.2022-0089

Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)

  • Integrin is a group of transmembrane glycoprotein that mediates cell-cell adhesion and signal transduction. It regulates cell adhesion, migration, proliferation, apoptosis and other functions. It is highly expressed on the surface of neovascular endothelial cells and a variety of malignant tumor cells. The peptides witharginine-glycine-aspartate (RGD) motif can specifically bind to multiplesubtypes of integrin including αVβ3. When labeled with radionuclides for single photon emission tomography (SPECT) or positron emission tomography (PET), the RGD-based peptides can non-invasively reveal the tumor characteristics, including invasion and metastasis, as well as evaluate angiogenesis in vivo. These methods have shown strong value in clinical application. Based on the home-and-abroad progress in relevant clinical research, this expert consensus aims to establish principles for clinical application of RGD-based peptides to integrin imaging.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return